AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Drug Development

FDA Approval of AbbVie Eye Drop a New Moment in Presbyopia Treatment

The decision made VUITY the very first and only eye drop to be approved for the Presbyopia treatment. Follow the article to know aspects of this new treatment.

November 1, 2021

2 min read

Kaylei Whalen

Bio NC

Clinical Catch-Up: October 25-29

Yet another busy week for clinical trial news. Here’s a look.

October 29, 2021

12 min read

Mark Terry

Drug Development

Alnylam and AbbVie Each Reveal Influential Phase III Results

After first reporting that its investigational RNAi drug vutrisiran hit its 9-month Phase III endpoints, Alnylam announced it continues to demonstrate positive results at the 18-month mark.

October 29, 2021

4 min read

Alex Keown

TARPEYO is the first FDA-approved drug for immunog

Drug Development

FDA OKs Gilead’s Pediatric HIV Treatment and Boehringer’s Humira Biosimilar

The U.S. FDA greenlit a new indication for Gilead Sciences’ drug Biktarvy for pediatric patients with HIV who are virologically suppressed or new to antiretroviral therapy.

October 18, 2021

3 min read

Alex Keown

Policy

Opioid Fight Clocks Another Win as Drug Distributors Reach Settlements

Teva Pharmaceuticals reached a $15 million agreement with the state of Louisiana to settle claims against the company over its marketing of opioid products.

September 30, 2021

3 min read

Alex Keown